Research view
Switch to patient viewMyelodysplastic syndromes: trials that stopped early
Trials on Myelodysplastic syndromes that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
86 stopped trials give a reason in the registry, latest registry update first.
Terminated
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Reason given in the registry “Change in corporate strategy”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Mar 2025.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Aptose Biosciences Inc.
- Registry record
- NCT04477291
Terminated
Blood Samples to Identify Biomarkers of Busulfan
Reason given in the registry “Study terminated due to end of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Mar 2025.
- Ended
- Oct 2024
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT02291965
Terminated
JSP191 (briquilimab) in Subjects with LR-MDS
Reason given in the registry “The study was terminated due to a lack of improvement in clinical efficacy outcomes.”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Feb 2025.
- Ended
- Oct 2024
- Phase
- Phase 1
- Run by
- Jasper Therapeutics, Inc.
- Registry record
- NCT05903274
Terminated
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Reason given in the registry “The sponsor is no longer supporting the drug”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Dec 2024.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- Washington University School of Medicine
- Registry record
- NCT04582864
Withdrawn
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Reason given in the registry “Lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.
- Ended
- Jun 2026
- Phase
- Phase 1
- Run by
- Leland Metheny
- Registry record
- NCT03939585
Terminated
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Reason given in the registry “Lack of Enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Nov 2024.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Hackensack Meridian Health
- Registry record
- NCT02846376
Withdrawn
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Oct 2024.
- Ended
- Mar 2025
- Run by
- Bristol-Myers Squibb
- Registry record
- NCT06581055
Withdrawn
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
Reason given in the registry “Withdrawn -ctms”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Feb 2026
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT05823480
Terminated
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
Reason given in the registry “Prematurely according to trial protocol”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2024.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- University of Leipzig
- Registry record
- NCT05178342
Withdrawn
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Reason given in the registry “Unable to accommodate FDA recommendations for protocol revisions”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jun 2024.
- Phase
- Phase 2
- Run by
- Northside Hospital, Inc.
- Registry record
- NCT06337331
Terminated
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
Reason given in the registry “Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).”
Quoted unchanged from ClinicalTrials.gov; record updated 6 May 2024.
- Ended
- Feb 2024
- Phase
- Phase 2
- Run by
- University of Leipzig
- Registry record
- NCT05237713
Withdrawn
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Reason given in the registry “PI has left IU with no plan to initiate study at IU”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Apr 2024.
- Ended
- Dec 2025
- Phase
- Phase 1/2
- Run by
- Indiana University
- Registry record
- NCT05895201
Withdrawn
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Reason given in the registry “waiting for update from Study Lead”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Apr 2024.
- Phase
- Phase 1/2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT05367401
Terminated
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
Reason given in the registry “The study was terminated after conducting an interim analysis of the available data where it became evident that the observed efficacy results were not in alignment with the initially set expectations.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Feb 2024.
- Ended
- Feb 2024
- Phase
- Phase 1
- Run by
- Hemavant Sciences GmbH
- Registry record
- NCT02841540
Withdrawn
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Reason given in the registry “Trial was stopped prematurely due to safety reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2024.
- Phase
- Phase 2
- Run by
- Uwe Platzbecker
- Registry record
- NCT05829434
Suspended
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Reason given in the registry “Slow enrollment and financial limitations”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Feb 2024.
- Ended
- Dec 2024
- Phase
- Phase 1/2
- Run by
- Cyclacel Pharmaceuticals, Inc.
- Registry record
- NCT05168904
Terminated
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Reason given in the registry “Company Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2024.
- Ended
- Jan 2024
- Phase
- Phase 1
- Run by
- Prelude Therapeutics Incorporated
- Registry record
- NCT05107856
Withdrawn
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Reason given in the registry “insufficient staff and updates in standard practice have made it difficult to recruit participants”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Dec 2023.
- Phase
- Phase 1/2
- Run by
- Naoyuki G. Saito, M.D., Ph.D.
- Registry record
- NCT05201183
Withdrawn
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Reason given in the registry “Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2023.
- Ended
- Jan 2026
- Phase
- Phase 2
- Run by
- Keros Therapeutics, Inc.
- Registry record
- NCT05927012
Suspended
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
Reason given in the registry “Suspended for changes in development strategy”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Feb 2023.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
- Registry record
- NCT04485065
Withdrawn
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Reason given in the registry “Change in development plan”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Oct 2022.
- Ended
- Nov 2025
- Phase
- Phase 1/2
- Run by
- Rhizen Pharmaceuticals SA
- Registry record
- NCT05246384
Withdrawn
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Reason given in the registry “The cusatuzumab MDS strategy is under revision”
Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2022.
- Ended
- Jan 2025
- Phase
- Phase 2
- Run by
- Janssen Research & Development, LLC
- Registry record
- NCT04264806
Withdrawn
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Reason given in the registry “No funding support”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Mar 2022.
- Ended
- Dec 2024
- Phase
- Phase 2
- Run by
- Washington University School of Medicine
- Registry record
- NCT04893915
Withdrawn
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Reason given in the registry “Medigene transfered all rights to a new Sponsor”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2021.
- Ended
- Jul 2025
- Phase
- Phase 1
- Run by
- Medigene AG
- Registry record
- NCT04464889
Withdrawn
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
Reason given in the registry “Sponsor Decision to Terminate Trial”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2021.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- Takeda
- Registry record
- NCT04985656
Withdrawn
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
Reason given in the registry “Administrative withdrawal by IRB”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Apr 2021.
- Phase
- Phase 1/2
- Run by
- Wake Forest University Health Sciences
- Registry record
- NCT03929211
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.